Zobrazeno 1 - 10
of 93
pro vyhledávání: '"B Kasimis"'
Autor:
J. Shultz, Nancy E. Kemeny, R. Isaacs, Charles D. Blanke, Malcolm J. Moore, John Cox, Daniel G. Haller, B. Kasimis, M. Modiano, Richard L. Schilsky, D. Carlin, J. Fleagle, L. Hammershaimb
Publikováno v:
Annals of Oncology. 13:87-91
Background Trimetrexate (TMTX) biochemically modulates 5-fluorouracil (5-FU) and leucovorin (LCV). Two phase II trials demonstrated promising activity for TMTX/5-FU/LCV in patients with untreated advanced colorectal cancer (ACC). This trial was desig
Autor:
Robert S. Stern, Jesse Mez, Robert C. Cantu, Christopher J. Nowinski, Melissa Mariani, Yorghos Tripodis, Michael L. Alosco, Brett M. Martin, Clifford A. Robbins, J Hayden, Christine M. Baugh, Alicia S. Chua, Michael D. McClean, A B Kasimis, Shannon Conneely, Ann C. McKee, Alcy Torres, Rhoda Au, Julie Stamm, Daniel H. Daneshvar, Christine E. Chaisson
Publikováno v:
Translational Psychiatry
Previous research suggests that age of first exposure (AFE) to football before age 12 may have long-term clinical implications; however, this relationship has only been examined in small samples of former professional football players. We examined th
Publikováno v:
Leukemia. 18:1433-1435
Waldenstrom's macroglobulinemia evolving into acute lymphoblastic leukemia: a case report and a review of the literature
Publikováno v:
Expert opinion on pharmacotherapy. 8(10)
This data were previously presented in February 2007 at the American Society of Clinical Oncology's Prostate Cancer Symposium in Orlando, FL, USA. COX-2 inhibition has shown promise in treating prostate cancer, but concerns exist regarding the risk p
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(3)
PURPOSE A phase II study to evaluate the response rate and toxicities of a trimetrexate, fluorouracil (5FU), and leucovorin regimen in patients with advanced incurable colorectal cancer. PATIENTS AND METHODS Thirty-six patients with unresectable or m
Publikováno v:
Cancer. 72(8)
Recent clinical trials have documented activity for combinations of chemotherapeutic agents that target the microtubular apparatus in patients with hormone-refractory prostate cancer. Taxol has a novel antimicrotubular mechanism, acting by stabilizin
Publikováno v:
Lung Cancer. 29:27-28
Autor:
W. H. Harvey, G. G. Monaghan, Paul J. Hesketh, D Gandara, Kelly Pendergrass, G Harker, D Oblon, B Kasimis, John D. Hainsworth, A Khojasteh
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 9(5)
Ondansetron (GR 38032F), a selective antagonist of serotonin subtype 3 receptors, is effective in the prevention of emesis associated with cisplatin as well as other chemotherapeutic agents. In this randomized, single-blind, multicenter, parallel gro
Publikováno v:
Clinical Oncology. 19:210
Autor:
Y. Alejandro, Q. Xia, V. Chang, P. Osenenko, Fengming Zhong, E. Morales, L. Duque, S. Srinivas, B. Kasimis, J. Cogswell, S. Hwang
Publikováno v:
The Journal of Pain. 6:S82